Fluvoxamine Trial Shows Promise for Long COVID Fatigue

0:00A new study dropped some hope for long COVID sufferers, showing the antidepressant flu-voxamine cuts fatigue and boost quality of life big time. Researchers from McMaster University, Brazil in the U.S. ran a trial on 399 adults still wiped out 90 days or more after. Their SARS-CoV-2 infection. At day 60 it'd be placebo hands down, with a 99% chance of real improvement. This cheap, easy-to-get SSRI works by hiking serotonin levels and fighting inflammation, which might be fueling that endless exhaustion. It's already out there for depression and OCD, so no big hurdles to grab it. Experts are buzzing. One prof calls it a game-changer for folks desperate for real fixes since long COVID fatigue hits like nothing else, keeping people glued to the couch. Another note, it could tame the immune overdrive behind the symptoms. But hold up, not everyone's soul yet. Some worry it might just be easing depression like fatigue mixed in with long COVID, so more

1:01trials are needed to confirm. Past research showed it helped acute COVID patients too, dodging death in ICU stays. Bottom line, this could open doors for off-label use without supply drama, especially with insurance covering most costs for many. Replications key, but it's a solid start toward relief. That wraps Canada News today, brought to you with AI. I'm Corey with The Story.